Off-patent Originator Drugs Could Disappear In China Over Next Decade: BCG Report
This article was originally published in PharmAsia News
Executive Summary
Multinational drug makers will see further pressure on branded generic sales that are unlikely to be offset by launches of new patented drugs in China. The issue creates an urgent need to accelerate product launches and switch to more cost-effective models.